Search results
Results from the WOW.Com Content Network
In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. [5] [7] [8] The company was named after Alnilam, a star in Orion's belt. The spelling was modified to make it unique. [9]
Alnylam (ALNY) delivered earnings and revenue surprises of -46.94% and 8.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
The company's shares have climbed more than 70% since it disclosed early results of the late-stage study of the drug, vutrisiran, in June. Vutrisiran was tested in patients with transthyretin ...
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a biotech company developing a new class of medications based on RNAi technology, have soared 250% since the start of 2013. Why are investors so ...
About Alnylam Pharmaceuticals. Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. ... Investor Relations and Corporate Communications or ...
Alnylam to Webcast Presentation at Upcoming Investor Conferences CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, today ...
About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. ... Investor Relations and Corporate Communications or ...
What: Shares of Alnylam Pharmaceuticals , a. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're ...